- Home
- FHI vs AKRO Comparison
FHI vs AKRO Comparison
Compare FHI & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHI
- AKRO
- Stock Information
- Founded
- FHI 1955
- AKRO 2017
- Country
- FHI United States
- AKRO United States
- Employees
- FHI N/A
- AKRO N/A
- Industry
- FHI Investment Managers
- AKRO Biotechnology: Pharmaceutical Preparations
- Sector
- FHI Finance
- AKRO Health Care
- Exchange
- FHI Nasdaq
- AKRO Nasdaq
- Market Cap
- FHI 3.4B
- AKRO 3.9B
- IPO Year
- FHI N/A
- AKRO 2019
- Fundamental
- Price
- FHI $42.46
- AKRO $54.20
- Analyst Decision
- FHI Hold
- AKRO Strong Buy
- Analyst Count
- FHI 6
- AKRO 6
- Target Price
- FHI $42.33
- AKRO $82.50
- AVG Volume (30 Days)
- FHI 884.0K
- AKRO 1.8M
- Earning Date
- FHI 07-24-2025
- AKRO 08-08-2025
- Dividend Yield
- FHI 3.21%
- AKRO N/A
- EPS Growth
- FHI 2.09
- AKRO N/A
- EPS
- FHI 3.58
- AKRO N/A
- Revenue
- FHI $1,659,262,000.00
- AKRO N/A
- Revenue This Year
- FHI $5.57
- AKRO N/A
- Revenue Next Year
- FHI $3.48
- AKRO N/A
- P/E Ratio
- FHI $11.82
- AKRO N/A
- Revenue Growth
- FHI 2.19
- AKRO N/A
- 52 Week Low
- FHI $31.59
- AKRO $21.02
- 52 Week High
- FHI $43.92
- AKRO $58.40
- Technical
- Relative Strength Index (RSI)
- FHI 53.81
- AKRO 62.96
- Support Level
- FHI $41.71
- AKRO $53.61
- Resistance Level
- FHI $42.92
- AKRO $56.49
- Average True Range (ATR)
- FHI 0.67
- AKRO 2.40
- MACD
- FHI -0.09
- AKRO -0.08
- Stochastic Oscillator
- FHI 66.42
- AKRO 65.93
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.